Ensysce Biosciences Reports First Quarter 2026 Financial Results
Rhea-AI Summary
Ensysce Biosciences (NASDAQ:ENSC) reported Q1 2026 results and clinical progress. Cash was $0.7 million at March 31, 2026 versus $4.3 million at year-end 2025, with a subsequent $2.0 million convertible preferred financing tranche closed in April.
Q1 federal grants were $1.0 million (down from $1.3 million). R&D expenses rose to $3.3 million from $1.9 million, G&A declined to $1.2 million from $1.4 million, and net loss widened to $3.6 million from $1.9 million. Operationally, Ensysce reached 50% interim enrollment in its pivotal PF614-301 Phase 3 trial, secured IRB approval for PF614-MPAR-102 Part 3, published peer-reviewed MPAR clinical data, gained a European patent allowance for ADHD candidate PF8026, advanced OUD candidate PF9001 with HEAL and NIDA support, and its Board launched a formal review of strategic alternatives.
AI-generated analysis. Not financial advice.
Positive
- Closed $2.0 million second tranche of convertible preferred financing in April 2026
- Federal grant funding of $1.0 million in Q1 2026 supports development programs
- R&D investment increased to $3.3 million, driven by PF614 Phase 3 activities
- Reached 50% interim enrollment target in pivotal PF614-301 Phase 3 pain trial
- Received IRB approval to initiate Part 3 of PF614-MPAR-102 overdose-protection study
- European Notice of Allowance for PF8026 ADHD patent strengthens IP estate
Negative
- Cash and cash equivalents declined to $0.7 million from $4.3 million
- Net loss widened to $3.6 million from $1.9 million year over year
- Federal grant funding decreased by $0.3 million versus prior-year quarter
- Higher R&D expenses, up $1.4 million year over year, increased burn rate
News Market Reaction – ENSC
On the day this news was published, ENSC gained 13.17%, reflecting a significant positive market reaction. Argus tracked a peak move of +11.5% during that session. Argus tracked a trough of -6.2% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $313K to the company's valuation, bringing the market cap to $2.69M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Before this release ENSC was down 3.82%, while scanner peers ARTL and NCNA were up 64.67% and 2.53% respectively. With mixed moves across other biotech peers and the scanner flagging no sector move, trading appeared stock-specific rather than driven by a broad industry trend.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Full-year 2025 earnings | Positive | +4.8% | Reported 2025 progress, PF614 Phase 3 start, MPAR patent and financial metrics. |
| Nov 14 | Q3 2025 earnings | Neutral | -4.8% | Q3 2025 results with PF614-301 initiation and new financing arrangements. |
| Aug 13 | Q2 2025 earnings | Positive | -4.2% | Q2 progress including PF614 Phase 3 initiation and MPAR-102 Part 2 completion. |
| May 13 | Q1 2025 earnings | Positive | +11.6% | Q1 2025 results, PF9001 patent, MPAR-102 Part 1 completion and funding metrics. |
| Mar 10 | Full-year 2024 earnings | Neutral | -4.8% | Full-year 2024 update with PF614 partnership, grant growth and loss improvement. |
Earnings releases have produced mixed reactions, with 3 negative and 2 positive next-day moves, suggesting no consistently favorable response to updates even when operational progress is highlighted.
Across the last five earnings-related updates from March 2024 through March 2026, Ensysce repeatedly emphasized advancement of PF614 into Phase 3, ongoing development of PF614-MPAR under Breakthrough Therapy designation, and expanding patent protection into 2042. Financially, cash levels have remained modest while R&D spending and net losses reflect continued investment in late-stage trials. Price reactions alternated between gains and declines, indicating that operational milestones alone have not guaranteed a positive share response.
Historical Comparison
In the past five earnings updates, ENSC’s average next-day move was about 0.51%, with both positive and negative reactions, indicating modest but inconsistent trading responses to financial results.
Earnings releases have tracked PF614’s progression into Phase 3, PF614-MPAR’s advancement under Breakthrough Therapy designation, and expanding patent coverage through 2042, while highlighting recurring financing actions to support ongoing development.
Regulatory & Risk Context
An effective S-3 shelf filed on 2026-04-08 registers up to 20,335,491 common shares for resale by existing securityholders. The company will not receive proceeds from these resales but may receive cash if investor warrants are exercised. The prospectus notes a going concern paragraph and disclosed cash funding operations into the second quarter of 2026.
Market Pulse Summary
The stock surged +13.2% in the session following this news. A strong positive reaction aligns with the article’s combination of clinical progress and a strategic review announcement. The quarter featured PF614 Phase 3 enrollment milestones, peer‑reviewed MPAR data, and IRB approval for the final PF614‑MPAR-102 stage, while cash fell to $0.7M with added $2.0M financing support. Historically, earnings moves averaged about 0.51%, so any outsized gain could prove sensitive to ongoing funding and execution risks.
Key Terms
institutional review board (irb) regulatory
phase 3 clinical trial medical
double-blind, placebo-controlled medical
breakthrough therapy designation regulatory
prodrug medical
plasma levels medical
convertible preferred stock financial
net loss financial
AI-generated analysis. Not financial advice.
~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~
~ Clinical Peer-Reviewed Data Published for First Overdose Protected Opioid PF614-MPAR®; Patent Estate Expanded ~
~ Company Launches Formal Review of Strategic Alternatives ~
SAN DIEGO, CA / ACCESS Newswire / May 15, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, today reported financial and operational results for the first quarter ended March 31, 2026.
"The first quarter of 2026 delivered meaningful operational and clinical momentum across our pipeline, underscoring the strength of our strategy and the discipline of our execution," said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce. We achieved
Dr. Kirkpatrick continued, "Following quarter-end, we closed a second financing tranche under an existing facility and secured IRB approval to initiate Part 3 of PF614-MPAR-102, the final stage of that study. Advancing this program strengthens the clinical evidence supporting a product we believe can fundamentally reshape how overdose risk is managed. In parallel, our Board has initiated a formal review of strategic alternatives, including potential partnerships and licensing opportunities, to accelerate the development of our TAAP™ and MPAR® platforms and unlock additional shareholder value."
TAAP™ (Opioid Abuse Deterrent Program) Update
PF614 is the Company's lead product candidate and represents what we believe could be a next‑generation extended‑release oxycodone with built‑in abuse protection. Developed using our proprietary Trypsin‑Activated Abuse Protection (TAAP™) technology, PF614 remains inactive until it is swallowed and exposed to trypsin in the small intestine, where it "switches on" to release oxycodone in a controlled manner.
This targeted activation is designed to deliver effective pain relief while significantly reducing the potential for manipulation or non‑oral abuse. By making the active drug inaccessible until it reaches the digestive tract, TAAP™ aims to provide a safer opioid option for patients with severe pain who require opioid‑strength therapy. The Company believes this approach has the potential to meaningfully differentiate PF614 within the multi‑billion‑dollar pain management market and address longstanding concerns around tampering and misuse.
In January, Ensysce announced that it had enrolled
MPAR® (Opioid Abuse Deterrent and Overdose Protection Program) Update
PF614-MPAR is the Company's next-generation combination product that integrates both the TAAP™ and MPAR® (Multi-Pill Abuse Resistance) technology to deliver effective opioid analgesia with the added benefit of built-in oral overdose protection. By pairing the PF614 prodrug with a trypsin inhibitor, PF614-MPAR is designed to "switch off" opioid release when supratherapeutic doses are taken, offering a differentiated safety profile aimed at reducing overdose risk while maintaining therapeutic efficacy for patients with severe pain.
Initial clinical data from the PF614-MPAR-101 study demonstrated that the MPAR® mechanism performed as intended at a 25 mg dose, providing the desired overdose protection. These results supported the FDA's decision to grant Breakthrough Therapy designation in January 2024, a key regulatory milestone that underscores the potential for PF614-MPAR to address a significant unmet need in opioid safety.
In March, Ensysce announced the publication of the first peer-reviewed clinical manuscript describing its MPAR® overdose protection technology in the January/February 2026 issue of the Journal of Opioid Management. The paper, "Formulation and a Phase 1 Clinical Study of PF614-MPAR, an Oxycodone Prodrug with Oral Opioid Overdose Protection," reported that PF614-MPAR achieved appropriate opioid plasma levels under normal dosing conditions while preventing large increases in exposure at supratherapeutic doses- reinforcing the potential for a fundamentally new safety paradigm in opioid analgesia.
Following quarter end, in April 2026, Ensysce received Institutional Review Board (IRB) approval to initiate Part 3 of the PF614-MPAR-102 study, the final stage in evaluating the MPAR® overdose-protection technology. Part 3 is designed to further characterize PF614-MPAR's protective effect across multiple dosing scenarios, building on the previously published data demonstrating that the product delivers therapeutic plasma levels under normal use while significantly limiting additional opioid exposure when higher-than-prescribed doses are taken. The study continues with support from the National Institute on Drug Abuse (NIDA), reflecting ongoing external validation of the program's potential impact.
ADHD Program Update
Ensysce is leveraging its TAAP™ and MPAR® platforms beyond pain management to develop what could become the first abuse-deterrent, overdose-protected stimulant therapies for attention-deficit/hyperactivity disorder (ADHD). The Company's ADHD pipeline includes PF8026, a novel immediate-release amphetamine prodrug, and PF8001, an extended-release candidate. In January 2026, Ensysce received a Notice of Allowance from the European Patent Office for a patent covering PF8026, with both composition-of-matter and method-of-use claims. This strengthens the Company's intellectual property position and supports long-term value creation as it allows advancement of safer stimulant options for a large and growing market. The need for innovation in ADHD therapeutics is significant. In 2023, approximately 3.9 million people aged 12 or older misused prescription stimulants, highlighting the limitations of current treatments and the urgency for products engineered to resist common routes of abuse and incorporate overdose protection mechanisms. By applying TAAP™ and MPAR® to stimulant medications, Ensysce has the ability to address this unmet need and expand its platform into another major therapeutic category with substantial commercial potential.
Opioid Use Disorder (OUD) Program Update
Beyond its pain management portfolio, Ensysce is advancing treatments for opioid use disorder (OUD) aimed at reducing cravings, lower relapse risk, and improving long-term patient outcomes while maintaining patient safety and quality of life. The Company has selected PF9001 as its lead OUD candidate and is evaluating it as a potential next-generation alternative to methadone, with the added advantage of built-in overdose protection, reduced cardiovascular risk and convenient oral delivery profile. The PF9001 program has been supported by a multi-year HEAL (Helping to End Addiction Long-Term) grant and in collaboration with NIDA. This program support provides both scientific validation and non‑dilutive funding, reinforcing the potential of PF9001 to address critical gaps in current OUD treatment options and expand the application of Ensysce's TAAP™ and MPAR® technologies into another major public health challenge.
Q1 2026 Financial Results
Cash - Cash and cash equivalents were
Federal Grants - Funding under federal grants totaled
Research & Development Expenses - R&D expenses were
General & Administrative Expenses - G&A expenses were
Net Income (Loss) - Net loss attributable to common stockholders for the first quarter of 2026 was
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. For more information, please visit www.ensysce.com.
Definitions
TAAP™: trypsin-activated abuse protection - designed to protect against prescription drug abuse.
MPAR®: multi-pill abuse resistance - designed to protect against abuse and accidental overdose.
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, possible NASDAQ delisting, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; continuation of government funding; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent annual report on Form 10-K and current reports on Form 8-K, available free of charge at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
Ensysce Biosciences, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
Three Months Ended March 31, | ||||||||
2026 | 2025 | |||||||
Federal grants | $ | 960,999 | $ | 1,319,772 | ||||
Operating expenses: | ||||||||
Research and development | 3,346,881 | 1,885,528 | ||||||
General and administrative | 1,176,348 | 1,401,756 | ||||||
Total operating expenses | 4,523,229 | 3,287,284 | ||||||
Loss from operations | (3,562,230 | ) | (1,967,512 | ) | ||||
Total other income (expense), net | 5,815 | 21,939 | ||||||
Net loss | $ | (3,556,415 | ) | $ | (1,945,573 | ) | ||
Net loss per share, basic and diluted | $ | (0.52 | ) | $ | (1.39 | ) | ||
Ensysce Biosciences, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Three Months Ended March 31, | ||||||||
2026 | 2025 | |||||||
Net cash used in operating activities | $ | (3,500,925 | ) | $ | (1,707,412 | ) | ||
Net cash (used in) provided by financing activities | (63,947 | ) | 1,257,826 | |||||
Change in cash and cash equivalents | (3,564,872 | ) | (449,586 | ) | ||||
Cash and cash equivalents at beginning of period | 4,310,354 | 3,502,077 | ||||||
Cash and cash equivalents at end of period | $ | 745,482 | $ | 3,052,491 | ||||
Ensysce Biosciences, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
March 31, | December 31, | |||||||
2026 | 2025 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 745,482 | $ | 4,310,354 | ||||
Prepaid expenses and other current assets | 1,263,058 | 2,934,664 | ||||||
Total current assets | 2,008,540 | 7,245,018 | ||||||
Other assets | 159,263 | 207,461 | ||||||
Total assets | $ | 2,167,803 | $ | 7,452,479 | ||||
Liabilities and stockholders' equity (deficit) | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 1,610,186 | $ | 3,267,610 | ||||
Accrued expenses and other liabilities | 980,780 | 993,411 | ||||||
Notes payable and accrued interest | 245,849 | 306,708 | ||||||
Total current liabilities | 2,836,815 | 4,567,729 | ||||||
Long-term liabilities | - | - | ||||||
Total liabilities | 2,836,815 | 4,567,729 | ||||||
Stockholders' equity (deficit) | (669,012 | ) | 2,884,750 | |||||
Total liabilities and stockholders' equity | $ | 2,167,803 | $ | 7,452,479 | ||||
SOURCE: Ensysce Biosciences
View the original press release on ACCESS Newswire